Search results
Results from the WOW.Com Content Network
Immunohistochemistry for CK7 of a metastatic undifferentiated carcinoma to a lymph node. Because the keratin-7 antigen is found in both healthy and neoplastic cells, antibodies to CK7 can be used in immunohistochemistry to distinguish ovarian and transitional cell carcinomas (staining positive) from colonic and prostate cancers (negative), respectively.
Tumor marker Associated tumor types Alpha fetoprotein (AFP) germ cell tumor, hepatocellular carcinoma [9] CA15-3: breast cancer [10] CA27.29: breast cancer [11] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [12] CA-125
CA 27-29. 2 languages. ... CA 27.29 is a tumor marker for breast cancer. [1] It is a form of glycoprotein MUC1. [2] References This page was last edited ...
Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy. The field of cancer immunology studies such topics.
This test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy. Oncotype DX looks at a panel of 21 genes in cells taken during tumor biopsy. The results of the test are given in the form of a recurrence score that indicates ...
Traditional prognostic markers in oncology include tumor size, staging, lymph node spreading status, and metastasis. Large tumor, late staging, presence of cancer cells in multiple distant lymph nodes, and observation of metastasis often associate with poor prognosis.
- The right panel shows high magnification on a positive area, confirming adenocarcinoma, as it shows tumor cells with large nuclei and prominent nucleoli. AE1/AE3 is an antibody cocktail that is used in immunohistochemistry , being generally positive in the cytoplasm of carcinomas (cancers of epithelial origin).
CA 27.29 (aka BR 27.29) and CA 15-3 measure different epitopes of the same protein antigen product of the MUC1 gene seen in breast cancer. CA 27.29 has enhanced sensitivity and specificity compared to CA 15-3 and is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer.